Imprivata
Imprivata sells badge-tap login and access software that hospitals use to get clinicians into systems fast.
On the record
Checkpoint: Thoma Bravo sale process expected to conclude, new owner picked
The call
Imprivata's grip on hospital login workflows has held for 20 years against bigger identity vendors, and the real question now is who buys it and what they do with it, not whether AI replaces it.
Imprivata makes login and access systems for hospitals, clinics, and medical devices. It is hard to replace because hospitals have spent years building these systems into their daily operations, connecting badges, computers, and patient records in ways that are tightly tied to healthcare rules and liability, and 4,000 hospitals already use it. Bigger rivals like Microsoft and Okta have tried and failed to take market share in hospitals over 20 years, even though they dominate other industries. The company is profitable and growing slowly, and is reportedly being shopped for sale at roughly $7 billion. The one thing that could change the picture is who buys it and how they run it after a sale, since a new owner might shift the company's direction, or the high sale price might leave little upside for employees and smaller shareholders.
Why
01
AI pressure: None apparent. AI agents needing governed identities is a new product line for Imprivata, not a threat eating its business. Could AI do the core job? Unlikely.
02
Bigger players: Microsoft Entra ID, Okta. Both sell horizontal identity tools but neither has cracked badge-tap, shared-workstation clinical login inside Epic and Cerner workflows. Could a giant copy it? No, they are blocked.
03
What protects it. Its software is wired into hospital badge readers, shared workstations, and Epic/Cerner logins across 4,000+ hospitals, so ripping it out means redoing clinical workflow for every nurse on every floor.
What would change this call
Announcement naming Imprivata's acquirer (strategic vs. PE vs. re-IPO) within 6-12 months. Shows whether new owner keeps or guts the standalone clinical-identity roadmap.
A fifth C-suite departure at Imprivata within six months. Would indicate real internal instability rather than pre-sale grooming.
Microsoft Entra or Epic announcing a clinical-workflow SSO deployment at a named hospital system. Would show the healthcare moat is finally being breached by a horizontal or EHR incumbent.
A fifth C-suite departure at Imprivata within six months. Would indicate real internal instability rather than pre-sale grooming.
Microsoft Entra or Epic announcing a clinical-workflow SSO deployment at a named hospital system. Would show the healthcare moat is finally being breached by a horizontal or EHR incumbent.
Key numbers
- ~$500M annual revenue
- 4,000+ hospitals, 4M+ daily clinician users
- Sale being explored at ~$7B valuation
Named risks
- Thoma Bravo sale process at ~$7B could bring a strategic acquirer that guts standalone product roadmap.
- Revenue figures diverge sharply between sources ($278M vs $500M), creating valuation and evidence uncertainty.
- Four C-suite changes (CPO, CTO, CRO, CMO) within about 18 months could signal turnover instability during a sale process.
- Emerging open standards for AI agent identity (Vint Cerf's DNSid, launched July 2026) could commoditize Imprivata's new agentic identity layer over 3 to 5 years.
- Non-healthcare vertical expansion (manufacturing, finance, logistics) competes directly with generic SSO/MFA from Microsoft and Okta, exposing weaker moat outside hospitals.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Microsoft Entra ID | contesting | Horizontal IAM leader but has not shipped a hospital clinical SSO taking real accounts as of mid-2026 |
| Okta | contesting | Competes on generic SSO/MFA but structurally absent from per-hospital clinical workflow integration as of 2026 |
| CyberArk | contesting | Overlaps in privileged access management (PAM) space where Imprivata added SecureLink and Verosint capabilities |
| Epic (EHR vendor) | contesting | Named as a potential future threat if it ships native clinical SSO, not yet realized as of 2026 |
Questions people ask
- Is Imprivata profitable in 2026?
- Imprivata is described as a profitable, mature business generating roughly $500 million in annual revenue as of February 2026, according to reporting on Thoma Bravo's sale exploration, though a separate data provider lists a lower $278.1M figure, creating some ambiguity.
- Who owns Imprivata?
- Thoma Bravo has owned Imprivata since completing a $544 million take-private acquisition on September 16, 2016. As of February 2026, Thoma Bravo engaged JPMorgan and Evercore to explore a sale valued at up to roughly $7 billion.
- Could AI replace Imprivata?
- Unlikely in healthcare. Imprivata's moat is deep clinical workflow integration (badge, EHR, HIPAA compliance) across 4,000+ organizations as of June 2026. It is also monetizing AI by launching 'Agentic Identity Management' at HIMSS26 in March 2026 to govern AI agents rather than be displaced by them.
- Is Imprivata laying off employees?
- No layoff signals found. Headcount trackers show modest growth, with employee counts trending upward year over year through 2025 and 2026, consistent with a stable, mature PE-owned company rather than a company in contraction.
- Who is Imprivata's biggest competitor?
- Microsoft Entra ID and Okta are the main horizontal identity incumbents, but despite roughly 20 years of opportunity neither has shipped a genuine healthcare clinical SSO product taking real hospital accounts from Imprivata as of mid-2026.
- What is Imprivata's flagship product?
- Imprivata's core platform includes single sign-on (originally OneSign), multi-factor authentication, and Confirm ID for controlled-substance e-prescribing. Its newest product, Agentic Identity Management, launched at HIMSS26 in March 2026 to govern AI agent access.
Timeline
- 2026-07Vint Cerf joins DNSid project to create durable identifiers for AI agents industry-wide
- 2026-06-11Imprivata expands into the Italian market
- 2026-04-09Imprivata appoints Cindy Zhou as Chief Marketing Officer
- 2026-03-10Imprivata launches Agentic Identity Management at HIMSS26
- 2026-02-02Thoma Bravo engages JPMorgan and Evercore to explore ~$7B sale of Imprivata
- 2025-10-24Imprivata acquires Verosint for AI-powered identity threat detection
- 2025-05-09Imprivata names Joel Burleson-Davis Chief Technology Officer
- 2025-01-22Imprivata names Carl Murphy Chief Revenue Officer
- 2024-07-16Imprivata appoints Chip Hughes Chief Product Officer
- 2016-09-16Thoma Bravo completes take-private acquisition of Imprivata for $544 million
Revision history
21 July 2026
First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Thoma Bravo taps JPMorgan to sell identity authentication firm Imprivata (2026-02-02)
- Thoma Bravo Completes Acquisition of Imprivata (2016-09-16)
- Imprivata - Overview, News & Similar companies (2026-07-18)
- Imprivata... Expands into the Italian Market (2026-06-11)
- Imprivata Number of Employees 2026 (2026-06-29)
- Imprivata Introduces Agentic Identity Management... Secure and Govern AI Agents (2026-03-10)
- Imprivata Acquires Verosint... (2025-10-24)
- Imprivata Appoints Cindy Zhou as Chief Marketing Officer (2026-04-09)
- Agentic ID? Vint Cerf Joins Project to Give Every AI Agent a Durable Identifier (2026-07-18)
- Imprivata - Headcount, Funding & Open Jobs (2026-07-08)
- EPCS: Complex DEA regulations require a comprehensive solution, not just a token